merck europe b.v. - tepotinib hydrochloride monohydrate - karcinoma, nesmulkiųjų ląstelių skausmas - antinavikiniai vaistai - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
Europos Sąjunga -
lietuvių -
EMA (European Medicines Agency)